Rexahn Pharmaceuticals Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction
ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,998,991, entitled “Neurotherapeutic treatment for sexual dysfunction.”
The patent covers a method for treating erectile dysfunction and premature ejaculation in males, as well as enhancing libido in females. Rick Soni, President of Rexahn, said, “We are very pleased to obtain this new US patent coverage for the neurotherapeutic treatment of sexual dysfunction, especially as we make progress in the development of Zoraxel®, currently in Phase II trials for erectile dysfunction.”
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ – all potential best in class therapeutics – and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit http://www.rexahn.com.
Rexahn Pharmaceuticals Announces US Patent Issued for CNS-based Treatment of Sexual Dysfunction
ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,998,991, entitled “Neurotherapeutic treatment for sexual dysfunction.”
The patent covers a method for treating erectile dysfunction and premature ejaculation in males, as well as enhancing libido in females. Rick Soni, President of Rexahn, said, “We are very pleased to obtain this new US patent coverage for the neurotherapeutic treatment of sexual dysfunction, especially as we make progress in the development of Zoraxel®, currently in Phase II trials for erectile dysfunction.”
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ – all potential best in class therapeutics – and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit http://www.rexahn.com.